.. BIO’s Policy Declaration addresses global health challenges Biotechnology Industry Corporation President and CEO released the next statement on a couple of options to boost access to medications in the developing globe which was announced in the Partnering for Global Wellness Forum 2010 today. We think that the goals of raising usage of medicines, respecting intellectual home rights, and maintaining commercial viability are supportive mutually.Using its SMART-linker technology platform, Catabasis has the capacity to gather the proven activities of salicylate and omega-3 fatty acids and clinically, as a total result, amplify the helpful ramifications of both compounds. The business is developing small molecules that would be available and effective with once-daily dosing orally. Catabasis’ lead candidates have demonstrated superb activity in a number of preclinical models of swelling and autoimmune diseases. The company has an extensive patent portfolio owned by Catabasis exclusively. Related StoriesWeight-loss surgery may be safe for managing type 2 diabetes in patients with moderate obesityNew Cleveland Clinic research shows bariatric surgery is safe option for managing type 2 diabetes in overweight or mildly obese patientsMayo Clinic investigators discover novel mechanism linked to diabetes riskThe company’s scientific advisory plank contains scientific leaders in neuro-scientific type 2 diabetes, immunology, and inflammation.